In a landmark move that has fundamentally reshaped the medical technology landscape, Abbott finalized its $21 billion acquisition of Exact Sciences in March. This massive integration not only solidifies Abbott’s footprint in the diagnostics sector—adding over $3 billion in annual revenue and pushing its diagnostics segment sales beyond the $12 billion mark—but also signals a strategic pivot toward a “longitudinal” model of cancer care. By combining Abbott’s global diagnostic scale with Exact Sciences’ pioneering work in genomic and molecular screening, the company is positioning itself to lead the next generation of cancer detection, treatment selection, and post-treatment monitoring.
The Chronology of a Diagnostic Powerhouse
The journey to this acquisition was paved by years of innovation and clinical validation from both entities. Exact Sciences established its market dominance through the success of the Cologuard stool-based colorectal cancer (CRC) test, which fundamentally altered screening compliance rates in the United States. Following the success of Cologuard, the company expanded its reach into precision medicine with the Oncotype DX genomic test, which assists physicians in determining the necessity of chemotherapy for breast, colon, and prostate cancer patients.
The momentum continued into 2025, a banner year for the company’s pipeline. Before the acquisition was fully realized, Exact Sciences introduced the Oncodetect molecular residual disease (MRD) test, designed to identify circulating tumor DNA in the blood post-treatment. This was followed by the launch of Cancerguard, a multi-cancer early detection (MCED) blood test.
Following the completion of the merger in March, the focus shifted to operational integration. Abbott is now tasked with leveraging its massive, global distribution infrastructure to scale these high-complexity molecular tests, while simultaneously refining its R&D strategy to address the "holy grail" of diagnostics: highly accurate, low-cost, blood-based screening.
Supporting Data: Why Cancer Diagnostics Matter
The financial and clinical stakes of this integration are enormous. Currently, the healthcare system struggles with a significant screening gap. Approximately 50 million Americans eligible for colorectal cancer screening remain unscreened, a statistic that correlates directly with higher late-stage diagnosis and mortality rates.
Recent data highlights the performance metrics Abbott is leveraging to close this gap:
- Cologuard Plus: The latest iteration of the flagship test boasts a 95% detection rate for colorectal cancer and 94% specificity, setting a benchmark for non-invasive screening options.
- The Screening Gap: Nearly 70% of all cancers lack a recommended routine screening option. This means seven out of ten cancer diagnoses occur only after symptoms appear or as incidental findings during unrelated medical procedures.
- The Economic Challenge: While blood-based tests (liquid biopsies) are often viewed as the future, they currently rely on expensive next-generation sequencing (NGS). Abbott’s internal research is focused on optimizing these costs to make them as accessible as the stool-based alternatives.
The Vision: Cancer as a Longitudinal Journey
In an exclusive interview with MedTech Dive, Jorge Garces, Abbott’s divisional vice president of cancer diagnostics R&D, emphasized that the company’s new philosophy treats cancer not as a single "event," but as a lifelong clinical journey.
“We envision this cancer care continuum from diagnosis through helping the physician make therapeutic decisions, and then monitoring the patient’s progress,” Garces explained.
Garces, who served as Chief Science Officer at Exact Sciences prior to the acquisition, shared a deeply personal perspective on the technology’s impact. Last year, his wife was diagnosed with breast cancer. By utilizing Abbott’s Riskguard hereditary testing and the Oncotype DX test, the couple was able to make informed decisions about surgical intervention and the necessity of chemotherapy. For his wife, the Oncotype DX test revealed a low risk of recurrence, sparing her the physical and psychological toll of unnecessary chemotherapy—an outcome shared by millions of women who have utilized the test.
Bridging the Gap: Blood-Based Testing and Strategic Partnerships
A critical component of Abbott’s current strategy is its partnership with Freenome. While internal development of a blood-based CRC test continues, the collaboration with Freenome provides a near-term solution for patients who are resistant to traditional stool-based screening or colonoscopies.
“We were very excited to see Freenome’s data,” Garces noted. “What has been very difficult with blood tests is the inability to detect precancer. Freenome’s test is currently at 18% precancer detection, which is best-in-class for blood-based options, though still trailing behind the gold-standard performance of Cologuard.”
Abbott holds the exclusive U.S. rights to commercialize these blood-based tests. According to Garces, the FDA is currently reviewing Freenome’s submission, with an approval expected in the near future. The long-term goal is to offer a tiered approach to screening: if a patient refuses the Cologuard test, the blood-based option provides a critical, secondary entry point to the care system, ensuring that no patient slips through the cracks.
The Future of Multi-Cancer Early Detection (MCED)
Perhaps the most ambitious aspect of the portfolio is the Cancerguard program. Because the prevalence of rare cancers is too low to justify individualized screening programs for each, the industry has turned toward an aggregate approach.
“The idea of a multi-cancer test is: what if we could provide a test to screen for all of them in aggregate?” Garces said. “That way, the chance of finding any one of those types increases, justifying the ability to screen the general population.”
Abbott has positioned Cancerguard as a complementary tool rather than a replacement. It is designed to be used in conjunction with established screenings like mammograms or Cologuard. The company recently launched the test in Japan and is preparing for a massive prospective clinical study in the U.S. to further validate its efficacy.
Strategic Implications for the Healthcare Market
The integration of these technologies into the Abbott portfolio has several profound implications for the medical industry:
- Standardization of Care: By providing a "full portfolio" of screening tools, Abbott is creating a closed-loop system that can guide a patient from initial screening to confirmation and, eventually, to treatment monitoring.
- Health Economics: The push to lower the cost of NGS-based blood tests is essential for global adoption. By bringing these costs down, Abbott aims to transition liquid biopsy from a luxury diagnostic to a standard of care that can be implemented in diverse, international healthcare markets.
- Speed to Resolution: One of the most significant challenges in cancer diagnostics is the "wait time" between a positive signal and a clinical diagnosis. Abbott’s current protocols are designed to provide a clear cancer signal that dictates a standardized follow-up pathway (CT/PET scans), significantly reducing the time to resolution.
Conclusion
The $21 billion acquisition of Exact Sciences is more than just a balance-sheet expansion for Abbott; it is a fundamental reconfiguration of how cancer will be managed in the coming decade. By integrating genomic insights, stool-based screening, and multi-cancer blood diagnostics, Abbott is attempting to solve the most persistent problem in oncology: the late-stage diagnosis of disease.
As the company moves forward, its success will hinge on its ability to prove that these advanced diagnostics are not only clinically superior but also economically viable for the general population. With a clear focus on the "cancer care continuum," Abbott is moving toward a future where early detection is not a matter of chance, but a routine, highly accurate, and accessible part of every patient’s medical journey.
